Vireo Growth Vergangene Ertragsentwicklung
Vergangenheit Kriterienprüfungen 0/6
Vireo Growth has been growing earnings at an average annual rate of 6.1%, while the Pharmaceuticals industry saw earnings growing at 46% annually. Revenues have been growing at an average rate of 23.7% per year.
Wichtige Informationen
6.1%
Wachstumsrate der Gewinne
20.4%
EPS-Wachstumsrate
| Pharmaceuticals Wachstum der Industrie | 23.1% |
| Wachstumsrate der Einnahmen | 23.7% |
| Eigenkapitalrendite | n/a |
| Netto-Marge | -17.5% |
| Nächste Ertragsaktualisierung | 13 Nov 2024 |
Jüngste Aktualisierungen vergangener Leistungen
Recent updates
Vireo Growth Inc.'s (CSE:VREO) 29% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Oct 12
Vireo Growth Inc. (CSE:VREO) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected
Aug 10Market Might Still Lack Some Conviction On Goodness Growth Holdings, Inc. (CSE:GDNS) Even After 30% Share Price Boost
Jun 01Goodness Growth Holdings, Inc. (CSE:GDNS) Stock Rockets 30% But Many Are Still Ignoring The Company
Apr 06Investors Still Aren't Entirely Convinced By Goodness Growth Holdings, Inc.'s (CSE:GDNS) Revenues Despite 59% Price Jump
Feb 01Goodness Growth Holdings (CSE:GDNS) Is Carrying A Fair Bit Of Debt
Dec 14Health Check: How Prudently Does Goodness Growth Holdings (CSE:GDNS) Use Debt?
Jul 14Is Vireo Health International (CSE:VREO) Weighed On By Its Debt Load?
Mar 19Did Business Growth Power Vireo Health International's (CSE:VREO) Share Price Gain of 127%?
Jan 25Aufschlüsselung der Einnahmen und Ausgaben
Wie Vireo Growth Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.
Gewinn- und Umsatzhistorie
| Datum | Einnahmen | Umsatz | Allgemeine und Verwaltungskosten | F&E-Ausgaben |
|---|---|---|---|---|
| 30 Jun 24 | 98 | -17 | 28 | 0 |
| 31 Mar 24 | 93 | -24 | 31 | 0 |
| 31 Dec 23 | 88 | -26 | 32 | 0 |
| 30 Sep 23 | 83 | -34 | 33 | 0 |
| 30 Jun 23 | 77 | -37 | 36 | 0 |
| 31 Mar 23 | 78 | -36 | 35 | 0 |
| 31 Dec 22 | 75 | -42 | 37 | 0 |
| 30 Sep 22 | 69 | -43 | 39 | 0 |
| 30 Jun 22 | 64 | -41 | 39 | 0 |
| 31 Mar 22 | 57 | -41 | 39 | 0 |
| 31 Dec 21 | 54 | -34 | 39 | 0 |
| 30 Sep 21 | 53 | -22 | 36 | 0 |
| 30 Jun 21 | 52 | -13 | 34 | 0 |
| 31 Mar 21 | 50 | -22 | 40 | 0 |
| 31 Dec 20 | 49 | -23 | 39 | 0 |
| 30 Sep 20 | 48 | -63 | 44 | 0 |
| 30 Jun 20 | 42 | -78 | 45 | 0 |
| 31 Mar 20 | 36 | -62 | 35 | 0 |
| 31 Dec 19 | 30 | -57 | 28 | 0 |
| 30 Sep 19 | 25 | -17 | 20 | 0 |
| 30 Jun 19 | 22 | -4 | 15 | 0 |
| 31 Mar 19 | 21 | -4 | 12 | 0 |
| 31 Dec 18 | 18 | -3 | 12 | 0 |
| 30 Sep 18 | 16 | -2 | 9 | 0 |
| 31 Dec 17 | 11 | 0 | 6 | 0 |
| 31 Dec 16 | 4 | 6 | 4 | 0 |
Qualität der Erträge: VREO is currently unprofitable.
Wachsende Gewinnspanne: VREO is currently unprofitable.
Analyse von freiem Cashflow und Gewinn
Analyse des Gewinnwachstums in der Vergangenheit
Ergebnisentwicklung: VREO is unprofitable, but has reduced losses over the past 5 years at a rate of 6.1% per year.
Beschleunigtes Wachstum: Unable to compare VREO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Erträge im Vergleich zur Industrie: VREO is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-40.8%).
Eigenkapitalrendite
Hohe Eigenkapitalrendite: VREO's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.